Cerity Partners LLC Has $23.97 Million Stake in STERIS plc $STE

Cerity Partners LLC boosted its holdings in shares of STERIS plc (NYSE:STE) by 28.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 96,853 shares of the medical equipment provider’s stock after buying an additional 21,656 shares during the period. Cerity Partners LLC owned about 0.10% of STERIS worth $23,966,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of STERIS by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock valued at $2,921,827,000 after acquiring an additional 205,276 shares in the last quarter. State Street Corp lifted its stake in STERIS by 2.4% during the second quarter. State Street Corp now owns 4,188,103 shares of the medical equipment provider’s stock worth $1,006,069,000 after purchasing an additional 98,220 shares during the period. Geode Capital Management LLC boosted its holdings in STERIS by 1.9% during the second quarter. Geode Capital Management LLC now owns 2,479,108 shares of the medical equipment provider’s stock valued at $592,980,000 after purchasing an additional 46,859 shares in the last quarter. Orbis Allan Gray Ltd grew its stake in shares of STERIS by 36.0% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock valued at $504,486,000 after purchasing an additional 556,088 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of STERIS by 3.9% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,346,039 shares of the medical equipment provider’s stock worth $323,345,000 after buying an additional 50,764 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

Insider Activity

In other STERIS news, VP John Adam Zangerle sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the completion of the sale, the vice president directly owned 33,669 shares of the company’s stock, valued at approximately $8,926,998.66. The trade was a 30.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Renato Tamaro sold 5,036 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the completion of the transaction, the vice president directly owned 5,695 shares in the company, valued at $1,466,747.25. This trade represents a 46.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 25,044 shares of company stock valued at $6,586,218 over the last 90 days. 1.07% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

STE has been the topic of a number of analyst reports. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $273.50.

STERIS Stock Down 1.5%

Shares of NYSE:STE opened at $256.77 on Friday. The company has a quick ratio of 1.63, a current ratio of 2.37 and a debt-to-equity ratio of 0.27. The firm has a market cap of $25.20 billion, a P/E ratio of 36.89 and a beta of 1.03. STERIS plc has a 12 month low of $204.28 and a 12 month high of $268.60. The company’s 50-day moving average price is $257.52 and its two-hundred day moving average price is $245.77.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. STERIS had a net margin of 12.07% and a return on equity of 14.43%. During the same period in the prior year, the business earned $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, research analysts forecast that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th were given a dividend of $0.63 per share. The ex-dividend date was Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. STERIS’s payout ratio is presently 36.21%.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.